Pith. sign in

REVIEW 4 cited by

DrugAgent: Reliable Multi-Agent Integration of Conflicting Biomedical Evidence for Drug-Target Interaction Assessment

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2408.13378 v5 pith:H2HE3IXP submitted 2024-08-23 cs.AI cs.CLcs.IRcs.LGq-bio.QM

DrugAgent: Reliable Multi-Agent Integration of Conflicting Biomedical Evidence for Drug-Target Interaction Assessment

classification cs.AI cs.CLcs.IRcs.LGq-bio.QM
keywords evidencedrugagentintegrationacrossassessmentcasesdrug-targetkinase
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved
0 comments
Share X Bluesky LinkedIn Reddit HN
read the original abstract

Workflows in drug-target interaction (DTI) assessment require integrating heterogeneous data from predictive models, curated resources, and observations from experimental literature. This evidence can be incomplete or conflicting. DrugAgent is a large language model (LLM)-based multi-agent system focused on DTI evidence integration that integrates outputs from machine learning, knowledge graph, and retrieval-augmented generation (RAG) agents. DrugAgent converts agent outputs into interpretable representations, then summarizes conflict across the evidence. We evaluated DrugAgent on kinase screening data of 900 pairs spanning 178 kinases and 42 inhibitors, and an androgen receptor antagonist screening benchmark. On the kinase dataset, LLM-as-a-Judge evaluation indicated outputs were faithful to input evidence in 98.8% of cases. Biological plausibility of returned summarization was high (scores 3-4 out of 5) across ground-truth classes: 79% of Weak activity labels cases (81% for Moderate/77% Strong); Strong cases received higher scores than Weak/Moderate. Label stability showed 98% agreement across runs. Results on the antagonist benchmark were consistent with the kinase dataset. Retrieved literature provided the greatest benefit when direct drug-target evidence was available, highlighting the importance of evidence availability for RAG-based integration. DrugAgent provides heterogeneous evidence-grounded DTI assessment, complementing standalone DTI prediction. We provide strategies to model agreement, conflict, and uncertainty in biomedical evidence integration. Code: https://github.com/sciluna/DrugAgent.

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Forward citations

Cited by 4 Pith papers

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score.

  1. Constraint-Aware Corrective Memory for Language-Based Drug Discovery Agents

    cs.AI 2026-04 unverdicted novelty 7.0

    CACM improves language-based drug discovery agents by 36.4% via protocol auditing, a grounded diagnostician, and compressed static/dynamic/corrective memory channels that localize failures and bias corrections.

  2. IR-Agent: Expert-Inspired LLM Agents for Structure Elucidation from Infrared Spectra

    cs.AI 2025-08 unverdicted novelty 6.0

    IR-Agent is a multi-agent LLM framework that emulates expert IR spectral analysis procedures to improve molecular structure elucidation accuracy and adaptability.

  3. ToolRL: Reward is All Tool Learning Needs

    cs.LG 2025-04 conditional novelty 6.0

    A principled reward design for tool selection and application in RL-trained LLMs delivers 17% gains over base models and 15% over SFT across benchmarks.

  4. From LLM Reasoning to Autonomous AI Agents: A Comprehensive Review

    cs.AI 2025-04 accept novelty 4.0

    A survey consolidating benchmarks, agent frameworks, real-world applications, and protocols for LLM-based autonomous agents into a proposed taxonomy with recommendations for future research.